semaglutide ckd approval FDA has approved Ozempic (semaglutide) to slow progression of chronic kidney disease in type 2 diabetes—first GLP‑1 under this indication, reducing risk by 24%. #glp_1 #GLP1 #CoreAgeRX #CoreAge #Core_Age_RX https://coreagerx.com VisualAbstract: Semaglutide Improves Outcomes in

While the medical community continues to unravel the exact mechanisms behind these invisible illnesses, researchers are increasingly pointing to a critical, overlapping pathophysiology: severe oxidative stress, mitochondrial dysfunction, and the total collapse of the body's natural detoxification pathways

Think of them as teammates, each with a different but important job

These lesions may appear as blue-gray or brown patches or lines

District Court for the District of Massachusetts granted summary judgment in favor of GlaxoSmithKline based on federal preemption i.e., that plaintiffs claims about GSKs labels, which were based on state law, were preempted by federal law, under which the FDA would not have allowed the types of label modifications plaintiffs argued GSK should have made

One day, a small molecule that targets this metabolite by blocking its transporter could potentially forestall breast cancer metastasis, with fewer side effects than sweeping therapies that target more general cellular processes

The news comes just as investors were losing hope in Hims